Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 24
Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026 Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026 공시 • Jan 25
Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026 Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026 공시 • Nov 10
Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025 Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025 공시 • Oct 29
Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025 Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh 공시 • Oct 21
Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025 Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025 공시 • Apr 24
Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025 Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025 공시 • Jan 23
Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025 Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025 New Risk • Nov 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m). 공시 • Nov 09
Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024 Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024 New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m). Declared Dividend • Oct 31
Dividend of ৳0.10 announced Dividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. 공시 • Oct 29
Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024 Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, Bangladesh New Risk • Oct 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m). 공시 • Oct 21
Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024 Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024 Reported Earnings • May 02
Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023) Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. 공시 • Apr 24
Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024 Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024 Reported Earnings • Feb 03
Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023) Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings. 공시 • Jan 24
Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024 Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024 Upcoming Dividend • Nov 27
Upcoming dividend of ৳0.10 per share at 0.5% yield Eligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%). 공시 • Nov 07
Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023 Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023 공시 • Oct 31
Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023 The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023. 공시 • Oct 30
Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023 Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. 공시 • Oct 20
Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023 Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023 Reported Earnings • May 17
Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022) Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Upcoming Dividend • Nov 27
Upcoming dividend of ৳0.30 per share Eligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Nov 01
Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022 The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares. Reported Earnings • May 28
Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021) Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years. Reported Earnings • Feb 09
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year. Upcoming Dividend • Nov 25
Upcoming dividend of ৳0.50 per share Eligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%). Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment improved over the past week After last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year. Reported Earnings • Feb 03
Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue. 공시 • Jul 17
Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020 Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020